{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:14:00Z","timestamp":1793513640738,"version":"4.5.0"},"reference-count":110,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,8,20]]},"abstract":"<jats:sec id=\"ab-jrv240013-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Obesity affects approximately 19% of women and 14% of men worldwide and is associated with increased morbidity. Antiobesity medications (AOMs) modify biological processes that affect appetite and significantly improve outcomes, such as type 2 diabetes, hypertension, and dyslipidemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv240013-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>AOMs should be administered in combination with lifestyle interventions and can be classified according to their mechanisms of action. Orlistat modifies digestive tract absorption and causes gastrointestinal adverse effects, such as oily fecal spotting and urgency, in more than 25% of patients. Centrally acting drugs, such as phentermine-topiramate and naltrexone-bupropion, regulate appetite in the brain and are associated with constipation in approximately 20% of patients, although the incidence of other adverse effects (eg, paresthesia, nausea) varies by medication. Nutrient-stimulated hormone-based medications, such as liraglutide, semaglutide, and tirzepatide, mimic the actions of enteropancreatic hormones that modify central appetite regulation and provide multiple cardiometabolic weight-loss benefits. Adverse effects of these drugs include nausea (28%-44%), diarrhea (21%-30%), and constipation (11%-24%). The relative potency of adult obesity medications has been studied in meta-analyses. Compared with placebo, orlistat was associated with 3.1% greater weight loss (52 randomized clinical trials [RCTs]; 16\u202f964 participants), phentermine-topiramate was associated with 8.0% greater weight loss (5 RCTs; 3407 participants), naltrexone-bupropion was associated with 4.1% greater weight loss (6 RCTs; 9949 participants), liraglutide was associated with 4.7% greater weight loss (18 RCTs; 6321 participants), semaglutide was associated with 11.4% greater weight loss (5 RCTs; 4421 participants), and tirzepatide 15 mg was associated with 12.4% greater weight loss (6 RCTs; 1972 participants).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv240013-3\">\n                    <jats:title>Conclusion and Relevance<\/jats:title>\n                    <jats:p>Obesity is associated with increased morbidity. Antiobesity medications are effective adjunctive therapy to lifestyle changes for improved weight loss and health outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2024.10816","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T11:02:11Z","timestamp":1721646131000},"page":"571","source":"Crossref","is-referenced-by-count":275,"title":["Medications for Obesity"],"prefix":"10.1001","volume":"332","author":[{"given":"Kimberly A.","family":"Gudzune","sequence":"first","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Kushner","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"},{"name":"Department of Medical Education, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"jrv240013r1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S2213-8587(22)00033-X","article-title":"Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study.","volume":"10","author":"Kivim\u00e4ki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"25","key":"jrv240013r2","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. state-level prevalence of adult obesity and severe obesity.","volume":"381","author":"Ward","year":"2019","journal-title":"N Engl J Med"},{"issue":"10431","key":"jrv240013r3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.","volume":"403","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"jrv240013r4","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/s42255-023-00864-1","article-title":"Differential mechanisms affecting weight loss and weight loss maintenance.","volume":"5","author":"Rosenbaum","year":"2023","journal-title":"Nat Metab"},{"issue":"6","key":"jrv240013r5","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.numecd.2022.02.016","article-title":"Turning the clock forward: new pharmacological and non pharmacological targets for the treatment of obesity.","volume":"32","author":"Ferrulli","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"jrv240013r6","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an Endocrine Society clinical practice guideline.","volume":"100","author":"Apovian","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"jrv240013r7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity.","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"issue":"5","key":"jrv240013r9","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA clinical practice guideline on pharmacological interventions for adults with obesity.","volume":"163","author":"Grunvald","year":"2022","journal-title":"Gastroenterology"},{"issue":"2","key":"jrv240013r10","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060640","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity.","volume":"151","author":"Hampl","year":"2023","journal-title":"Pediatrics"},{"issue":"2","key":"jrv240013r11","doi-asserted-by":"publisher","DOI":"10.1111\/obr.v24.2","article-title":"Obesity in South and Southeast Asia\u2014a new consensus on care and management.","volume":"24","author":"Tham","year":"2023","journal-title":"Obes Rev"},{"issue":"2","key":"jrv240013r14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/jama.2022.22974","article-title":"Association between regulatory submission characteristics and recalls of medical devices receiving 510(k) clearance.","volume":"329","author":"Everhart","year":"2023","journal-title":"JAMA"},{"issue":"10434","key":"jrv240013r15","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S0140-6736(24)00351-9","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.","volume":"403","author":"Shi","year":"2024","journal-title":"Lancet"},{"issue":"9123","key":"jrv240013r16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients.","volume":"352","author":"Sj\u00f6str\u00f6m","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"jrv240013r17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP).","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"issue":"9741","key":"jrv240013r18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"jrv240013r19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management.","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"jrv240013r20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv240013r21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity.","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"23","key":"jrv240013r22","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","article-title":"Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.","volume":"293","author":"Chanoine","year":"2005","journal-title":"JAMA"},{"issue":"1","key":"jrv240013r23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"issue":"11","key":"jrv240013r24","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/oby.v21.11","article-title":"Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults.","volume":"21","author":"Aronne","year":"2013","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"jrv240013r30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007654.pub5","article-title":"Long-term effects of weight-reducing drugs in people with hypertension.","volume":"1","author":"Siebenhofer","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"jrv240013r31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","article-title":"Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.","volume":"2005","author":"Norris","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"jrv240013r34","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.2337\/dc14-0930","article-title":"Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"issue":"12","key":"jrv240013r35","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"issue":"7","key":"jrv240013r36","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial.","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"10278","key":"jrv240013r37","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"10402","key":"jrv240013r38","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"jrv240013r39","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/oby.v32.3","article-title":"Early- and later-stage persistence with antiobesity medications: a retrospective cohort study.","volume":"32","author":"Gasoyan","year":"2023","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"jrv240013r40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","article-title":"Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.","volume":"22","author":"Zhou","year":"2024","journal-title":"BMC Med"},{"issue":"2","key":"jrv240013r41","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/oby.2019.27.issue-2","article-title":"A randomized, double-blind, placebo-controlled study of Gelesis100: a novel nonsystemic oral hydrogel for weight loss.","volume":"27","author":"Greenway","year":"2019","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"jrv240013r42","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s13679-023-00546-9","article-title":"Phentermine in the modern era of obesity pharmacotherapy: does it still have a role in treatment?","volume":"13","author":"Lewis","year":"2024","journal-title":"Curr Obes Rep"},{"issue":"12","key":"jrv240013r43","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1002\/oby.v27.12","article-title":"Antiobesity medication use in 2.2 million adults across eight large health care organizations: 2009-2015.","volume":"27","author":"Saxon","year":"2019","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"jrv240013r44","doi-asserted-by":"publisher","DOI":"10.1111\/cob.v13.5","article-title":"Use of medications associated with weight change among participants in the All of Us research programme.","volume":"13","author":"Almazan","year":"2023","journal-title":"Clin Obes"},{"issue":"5","key":"jrv240013r46","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2337\/dc16-2427","article-title":"Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial.","volume":"40","author":"Hollander","year":"2017","journal-title":"Diabetes Care"},{"issue":"4","key":"jrv240013r47","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/oby.2019.27.issue-4","article-title":"Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort.","volume":"27","author":"Lewis","year":"2019","journal-title":"Obesity (Silver Spring)"},{"issue":"9774","key":"jrv240013r49","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"jrv240013r50","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"jrv240013r51","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200014","article-title":"Phentermine\/topiramate for the treatment of adolescent obesity.","volume":"1","author":"Kelly","year":"2022","journal-title":"NEJM Evid"},{"issue":"5","key":"jrv240013r52","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/s41366-020-0544-4","article-title":"The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System database.","volume":"44","author":"Gorelik","year":"2020","journal-title":"Int J Obes (Lond)"},{"issue":"1","key":"jrv240013r53","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"jrv240013r54","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/oby.v21.5","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II).","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity (Silver Spring)"},{"issue":"10","key":"jrv240013r56","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jama.2016.1558","article-title":"Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial.","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"jrv240013r57","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.3390\/ijms24043384","article-title":"Hormonal gut-brain signaling for the treatment of obesity.","volume":"24","author":"Roh","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"jrv240013r58","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1.","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"6","key":"jrv240013r59","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s42255-023-00812-z","article-title":"Gut hormone co-agonists for the treatment of obesity: from bench to bedside.","volume":"5","author":"Nogueiras","year":"2023","journal-title":"Nat Metab"},{"issue":"2","key":"jrv240013r60","doi-asserted-by":"publisher","DOI":"10.1111\/obr.v23.2","article-title":"The incretin\/glucagon system as a target for pharmacotherapy of obesity.","volume":"23","author":"Del Prato","year":"2022","journal-title":"Obes Rev"},{"issue":"8","key":"jrv240013r61","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.3390\/jcm11082207","article-title":"Mediators of amylin action in metabolic control.","volume":"11","author":"Boyle","year":"2022","journal-title":"J Clin Med"},{"issue":"7","key":"jrv240013r62","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"jrv240013r63","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP.","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"issue":"3","key":"jrv240013r64","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.v39.3","article-title":"Glucagon in type 2 diabetes: friend or foe?","volume":"39","author":"Caruso","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"key":"jrv240013r65","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1146\/med.2023.74.issue-1","article-title":"New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics.","volume":"74","author":"Jastreboff","year":"2023","journal-title":"Annu Rev Med"},{"issue":"6","key":"jrv240013r66","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/s41591-021-01394-7","article-title":"Another milestone in the evolution of GLP-1-based diabetes therapies.","volume":"27","author":"Nauck","year":"2021","journal-title":"Nat Med"},{"key":"jrv240013r67","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide.","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"jrv240013r68","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"issue":"11","key":"jrv240013r69","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study.","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"jrv240013r70","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/oby.v28.3","article-title":"Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial.","volume":"28","author":"Wadden","year":"2020","journal-title":"Obesity (Silver Spring)"},{"issue":"10077","key":"jrv240013r71","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"},{"issue":"22","key":"jrv240013r72","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity.","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv240013r73","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv240013r74","doi-asserted-by":"publisher","DOI":"10.1111\/obr.v22.1","article-title":"Cardiovascular outcome trials in obesity: a review.","volume":"22","author":"Wilding","year":"2021","journal-title":"Obes Rev"},{"issue":"6","key":"jrv240013r75","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/oby.22794","article-title":"Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5.","volume":"28","author":"Kushner","year":"2020","journal-title":"Obesity (Silver Spring)"},{"issue":"14","key":"jrv240013r76","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial.","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"14","key":"jrv240013r77","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial.","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"10","key":"jrv240013r78","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"jrv240013r79","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an East Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"jrv240013r80","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial.","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"24","key":"jrv240013r81","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity.","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"jrv240013r82","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes.","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"jrv240013r83","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity.","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv240013r84","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/dom.v24.1","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"jrv240013r85","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41366-023-01337-x","article-title":"Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.","volume":"47","author":"de Mesquita","year":"2023","journal-title":"Int J Obes (Lond)"},{"issue":"1","key":"jrv240013r86","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/oby.v31.1","article-title":"Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program.","volume":"31","author":"le Roux","year":"2023","journal-title":"Obesity (Silver Spring)"},{"issue":"11","key":"jrv240013r87","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"jrv240013r88","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial.","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"9","key":"jrv240013r90","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1111\/dom.v25.9","article-title":"Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: an indirect treatment comparison.","volume":"25","author":"le Roux","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"jrv240013r91","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-024-01473-y","article-title":"What is the pipeline for future medications for obesity?","author":"Melson","year":"2024","journal-title":"Int J Obes (Lond)"},{"issue":"10286","key":"jrv240013r92","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial.","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"jrv240013r93","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"jrv240013r94","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial.","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"10403","key":"jrv240013r95","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"jrv240013r96","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity.","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv240013r97","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.33457","article-title":"Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial.","volume":"4","author":"Heymsfield","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"11","key":"jrv240013r99","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1001\/jama.2018.13022","article-title":"Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US Preventive Services Task Force recommendation statement.","volume":"320","author":"Curry","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"jrv240013r100","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s13679-023-00534-z","article-title":"The role of lifestyle modification with second-generation antiobesity medications: comparisons, questions and clinical opportunities.","volume":"12","author":"Wadden","year":"2023","journal-title":"Curr Obes Rep"},{"issue":"11","key":"jrv240013r101","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jama.2012.9931","article-title":"Cardiovascular risk assessment in the development of new drugs for obesity.","volume":"308","author":"Hiatt","year":"2012","journal-title":"JAMA"},{"issue":"2","key":"jrv240013r102","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1517\/14740338.2015.995088","article-title":"Why are antiobesity drugs stigmatized?","volume":"14","author":"Halpern","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl 4","key":"jrv240013r103","doi-asserted-by":"publisher","DOI":"10.1111\/obr.v22.S4","article-title":"Exercise training in the management of overweight and obesity in adults: synthesis of the evidence and recommendations from the European Association for the Study of Obesity physical activity working group.","volume":"22","author":"Oppert","year":"2021","journal-title":"Obesity Rev"},{"issue":"6","key":"jrv240013r104","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1249\/MSS.0000000000001938","article-title":"Physical activity and the prevention of weight gain in adults: a systematic review.","volume":"51","author":"Jakicic","year":"2019","journal-title":"Med Sci Sports Exerc"},{"issue":"2","key":"jrv240013r105","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.56183","article-title":"Weight loss treatment and longitudinal weight change among primary care patients with obesity.","volume":"7","author":"Henderson","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"11","key":"jrv240013r106","doi-asserted-by":"publisher","DOI":"10.1111\/obr.v22.11","article-title":"Clinical outcomes associated with antiobesity medications in real-world practice: a systematic literature review.","volume":"22","author":"Ahmad","year":"2021","journal-title":"Obes Rev"},{"issue":"8","key":"jrv240013r107","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.v24.8","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension.","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"jrv240013r109","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1002\/oby.2018.26.issue-12","article-title":"Coverage for obesity prevention and treatment services: analysis of Medicaid and state employee health insurance programs.","volume":"26","author":"Jannah","year":"2018","journal-title":"Obesity (Silver Spring)"},{"key":"jrv240013r110","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CEOR.S392276","article-title":"The relative value of antiobesity medications compared to similar therapies.","volume":"15","author":"Kim","year":"2023","journal-title":"Clinicoecon Outcomes Res"},{"key":"jrv240013r8","unstructured":"Pedersen? SD, Manjoo? P, Wharton? S. Canadian adult obesity clinical practice guidelines: pharmacotherapy for obesity management. Accessed April 14, 2024. https:\/\/obesitycanada.ca\/guidelines\/pharmacotherapy\/"},{"key":"jrv240013r12","unstructured":"Xenical package insert. Accessed April 14, 2024. https:\/\/xenical.com\/pdf\/PI_Xenical-brand_FINAL.PDF"},{"key":"jrv240013r13","unstructured":"Plenity instructions for use. Accessed April 14, 2024. https:\/\/www.myplenity.com\/siteassets\/components\/pdfs\/acq_hcp_plenity-physician-ifu_march_2021.pdf"},{"key":"jrv240013r25","unstructured":"Qsymia package insert. Accessed April 14, 2024. https:\/\/qsymia.com\/patient\/include\/media\/pdf\/prescribing-information.pdf"},{"key":"jrv240013r26","unstructured":"Contrave package insert. Accessed April 14, 2024. https:\/\/contravehcp.com\/wp-content\/uploads\/Contrave_PI.pdf"},{"key":"jrv240013r27","unstructured":"Saxenda package insert. Accessed April 14, 2024. https:\/\/www.novo-pi.com\/saxenda.pdf"},{"key":"jrv240013r28","unstructured":"Wegovy package insert. Accessed April 14, 2024. https:\/\/www.novo-pi.com\/wegovy.pdf"},{"key":"jrv240013r29","unstructured":"Zepbound package insert. Accessed April 14, 2024. https:\/\/uspl.lilly.com\/zepbound\/zepbound.html#pi"},{"key":"jrv240013r32","unstructured":"Adipex package insert. Accessed April 14, 2024. https:\/\/www.adipex.com\/globalassets\/adipex\/adipex_pi.pdf"},{"key":"jrv240013r33","unstructured":"Lomaira package insert. Accessed April 14, 2024. https:\/\/lomaira.com\/Prescribing_Information.pdf"},{"key":"jrv240013r45","unstructured":"Bray? GA, Purnell? JQ. An historical review of steps and missteps in the discovery of antiobesity drugs. 2000. Accessed April 14, 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/35834619\/"},{"key":"jrv240013r48","unstructured":"European Medicines Agency. Qsvia: phentermine\/topiramate. Accessed April 13, 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/qsiva"},{"key":"jrv240013r55","unstructured":"Wellbutrin XL package insert. Accessed April 13, 2024. https:\/\/pi.bauschhealth.com\/globalassets\/BHC\/PI\/WellbutrinXL-PI.pdf"},{"key":"jrv240013r89","unstructured":"NCT05556512. A study of tirzepatide (LY3298176) on the reduction on morbidity and mortality in adults with obesity. Accessed April 14, 2024. https:\/\/clinicaltrials.gov\/study\/NCT05556512"},{"key":"jrv240013r98","unstructured":"Long-term Effectiveness of the Antiobesity Medication Phentermine (LEAP). NCT05176626. Accessed April 14, 2024. https:\/\/clinicaltrials.gov\/study\/NCT05176626"},{"key":"jrv240013r108","unstructured":"Waidmann? TA, Waxman? E, Pancini? V, Gupta? P, Phillip Tabb? L. Obesity Across America. Accessed March 4, 2024. https:\/\/www.urban.org\/sites\/default\/files\/2022-02\/obesity-across-america.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2821290\/jama_gudzune_2024_rv_240013_1723483048.36481.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T11:05:37Z","timestamp":1724151937000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2821290"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":110,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,8,20]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.10816","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,20]]}}}